[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100493782":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":37,"locations":44,"responsibleParty":61,"collaborators":63,"id":67,"slug":42,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":42,"enrollmentInfo":75,"targetDuration":42,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":46,"whyStopped":42,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Kindai University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"No aspirin (Prasugrel monotherapy)","ACTIVE_COMPARATOR","To start prasugrel monotherapy before primary percutaneous coronary intervention (PCI).",[13],"Drug: No aspirin (Prasugurel monotherapy)",{"label":15,"type":10,"description":16,"interventionNames":17},"12-month DAPT","To start dual antiplatelet therapy with prasugrel and aspirin for 12 months before primary percutaneous coronary intervention (PCI).",[18],"Drug: 12-month DAPT",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","No aspirin (Prasugurel monotherapy)","12-month prasugrel monotherapy",[9],[26],"Experimental arm",{"type":21,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"12-month dual antiplatelet therapy with prasugrel and aspirin",[15],[31],"Reference arm",[33],{"name":34,"affiliation":35,"role":36},"Gaku Nakazawa, MD, PhD","Kindai University Faculty of Medicine","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Kuniaki Takahashi, MD, PhD","CONTACT","+81-72-366-0221",null,"kuniaki.t.0125@gmail.com",[45],{"facility":35,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Sayama","Osaka","589-8511","Japan","JP",{"type":53,"coordinates":54},"Point",[55,56],135.56298,34.51685,{"lat":56,"lon":55},[59,60],{"name":34,"role":40,"phone":42,"phoneExt":42,"email":42},{"name":39,"role":40,"phone":42,"phoneExt":42,"email":42},{"type":62,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR",[64],{"name":65,"class":66},"Boston Scientific Corporation","INDUSTRY","100493782",false,"NCT05709626","PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction","PREMIUM","Inclusion Criteria:\n\n* Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM)\n* STEMI patients\n* Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months\n\nExclusion Criteria:\n\n* Patients taking anticoagulants\n* Patients under 18 years old\n* Patients with less than 1 year prognosis\n* Patients participating in other intervention studies","ALL","18 Years",{"count":76,"type":77},2258,"ESTIMATED","INTERVENTIONAL",[80],"PHASE4","The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).",[83],"ST-segment Elevation Myocardial Infarction (STEMI)",[85,86,87,88,89],"Acute Coronary Syndrome","Dual AntiPlatelet Therapy","Drug Eluting Stent","Percutaneous Coronary Intervention","ST-elevation myocardial infarction","2023-02-28",{"date":92,"type":93},"2023-03-01","ACTUAL",{"date":90,"type":77},{"date":96,"type":77},"2028-01-04",{"name":5,"class":6},1]